Healthcare -
Biotechnology - NASDAQ - US
$ 1.98
-2.46 %
$ 47.4 M
Market Cap
-0.75
P/E
1. INTRINSIC VALUE
Balance Sheet
Celularity Inc.
| Current Assets | 20.6 M |
| Cash & Short-Term Investments | 738 K |
| Receivables | 13.6 M |
| Other Current Assets | 6.27 M |
| Non-Current Assets | 112 M |
| Long-Term Investments | 0 |
| PP&E | 72.4 M |
| Other Non-Current Assets | 39.7 M |
| Current Liabilities | 53.7 M |
| Accounts Payable | 23.3 M |
| Short-Term Debt | 2.48 M |
| Other Current Liabilities | 27.9 M |
| Non-Current Liabilities | 70.2 M |
| Long-Term Debt | 26.5 M |
| Other Non-Current Liabilities | 43.6 M |
EFFICIENCY
Earnings Waterfall
Celularity Inc.
| Revenue | 54.2 M |
| Cost Of Revenue | 15 M |
| Gross Profit | 45.3 M |
| Operating Expenses | 77.6 M |
| Operating Income | -38.4 M |
| Other Expenses | 19.5 M |
| Net Income | -57.9 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Celularity Inc.
| Net Income | -57.9 M |
| Depreciation & Amortization | 7.92 M |
| Capital Expenditures | -161 K |
| Stock-Based Compensation | 11.6 M |
| Change in Working Capital | 0 |
| Others | 0 |
| Free Cash Flow | -6.56 M |
Wall Street Analysts Price Targets
Celularity Inc.
CELU has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
CELU does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Celularity Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Celularity Hails New Florida Law Opening Patient Access to Stem Cell Therapies
New law goes into effect on July 1st authorizing Florida physicians to provide stem cell therapies to their patients for orthopedics, wound care, and pain management FLORHAM PARK, N.J., July 01, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company, today hailed a new Florida law taking effect today that opens the door to physicians' use of investigational stem cell therapies in the state in orthopedics, wound care, and pain management.
globenewswire.com
- 2 weeks ago
Celularity Announces Chief Financial Officer Transition
Celularity retains financial and business advisor to provide outsourced accounting and consulting services during the transition period Celularity retains financial and business advisor to provide outsourced accounting and consulting services during the transition period
globenewswire.com
- 1 month ago
Celularity Announces Publication Advancing Ocular Surface Reconstruction with Tri-Layer Amniotic Membrane Technology
Highlights the unique potential of Celularity's proprietary advanced biomaterial technology as a novel cellular delivery system for ocular surface reconstruction Supports broad range of regenerative medicine applications beyond ophthalmology FLORHAM PARK, N.J., June 02, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company, today announced its research published in the May 29, 2025, issue of the peer-reviewed journal Regenerative Engineering and Translational Medicine, a leading open-access journal publishing cutting-edge advances in regenerative medicine.
globenewswire.com
- 1 month ago
Celularity Receives Nasdaq Notice Regarding Form 10-Q
FLORHAM PARK, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a cellular and regenerative medicine company, today announced that on May 28, 2025, Nasdaq notified the Company that it did not timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2025. Based on this latest notice, the Company is not in compliance with Listing Rule 5250 (c)(1), which requires the Company to timely file all required periodic financial reports with the Securities and Exchange Commission.
globenewswire.com
- 1 month ago
Celularity Announces Full Year 2024 Operating and Financial Results
Net revenues for the year ending December 31, 2024, totaled $54.2 million, an increase of $31.4 million, or 138.1%, compared to the previous year. Net revenues for the year ending December 31, 2024, totaled $54.2 million, an increase of $31.4 million, or 138.1%, compared to the previous year.
globenewswire.com
- 2 months ago
Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees
FLORHAM PARK, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a cellular and regenerative medicine company, today announced that Nasdaq has notified the Company that it has not paid certain fees required by Listing Rule 5250(f) and accordingly the Company will be delisted unless it appeals this determination. The Company's past due fee balance totaled $70,000. On April 25, 2025, the Company paid in full the fee balance owed to Nasdaq.
globenewswire.com
- 2 months ago
Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products
Action delays to January 1, 2026, the effective date of a Biden-era Medicare LCD for skin substitute products used to treat diabetic foot ulcers and venous leg ulcers Action delays to January 1, 2026, the effective date of a Biden-era Medicare LCD for skin substitute products used to treat diabetic foot ulcers and venous leg ulcers
globenewswire.com
- 3 months ago
Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products
Natalin and Acelagraft™ are the latest additions to Celularity's portfolio of HCT/P 361 products for use in the treatment of partial and full thickness acute and chronic wounds Natalin and Acelagraft™ are the latest additions to Celularity's portfolio of HCT/P 361 products for use in the treatment of partial and full thickness acute and chronic wounds
globenewswire.com
- 4 months ago
Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company
FLORHAM PARK, N.J., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a cellular and regenerative medicine company, today announced that it has entered into a Master Services Collaboration Agreement with BlueSphere Bio, Inc. (BSB) covering manufacturing activities for certain BSB cell therapy products.
globenewswire.com
- 4 months ago
Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter
FLORHAM PARK, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company, today announced that it has received a letter from the Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”), confirming that Celularity has regained compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”). Following the filing of its Quarterly Report on Form 10-Q for the period ended September 30, 2024, Nasdaq has determined that the matter is now closed.
globenewswire.com
- 7 months ago
Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023
FLORHAM PARK, N.J., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company, today announced that it filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024. With this filing, the Company is now current on its quarterly report filings.
globenewswire.com
- 7 months ago
Celularity Inc. Announces Receipt of Nasdaq Notification
FLORHAM PARK, N.J., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced that on November 21, 2024, the Company received notification from the Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company does not comply with the Nasdaq continued listing requirements due to the Company's inability to timely file its Quarterly Report on Form 10-Q for the period ended September 30, 2024 (the “Q3 Form 10-Q”). Nasdaq's notice has no immediate effect on the listing of Celularity's common stock and warrants, which continue to trade on the Nasdaq Capital Market under the symbols “CELU” and “CELUW,” respectively.
globenewswire.com
- 7 months ago
8. Profile
Summary
Celularity Inc. CELU
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 47.4 M
Dividend Yield
0.00%
Description
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.
Contact
170 Park Avenue, Florham Park, NJ, 07932
https://www.celularity.com
IPO
Date
Aug. 8, 2019
Employees
120
Officers
Mr. Carlos Ramirez
SVice President of Investor Relations
Dr. Stephen A. Brigido D.P.M.
President of Degenerative Diseases
Mr. David Jakob Lemus CPA, M.S., MBA
Treasurer
Mr. Tim Wilk
Senior Vice President of Technical Operations
Mr. John R. Haines
Senior EVice President, Corporate Secretary, Global Manager & Chief Administrative Officer
Dr. Robert Joseph Hariri M.D., Ph.D.
Founder, Chief Executive Officer & Chairman
Mr. David C. Beers C.F.A.
Chief Financial Officer
Sharmila Koppisetti M.D.
Senior Vice President of Clinical Dev. Immunology & Drug Safety